Harnessing Innate Immunity Using Biomaterials for Cancer Immunotherapy

Area of Science:

• Oncology
• Immunology
• Biomaterials Science

Background:

• Immune checkpoint blockade revolutionized immuno-oncology, but T cell-based therapies benefit limited patients.
• Current strategies focus on adaptive immunity (T cells), highlighting a need for next-generation immunotherapies.
• Maximizing therapeutic potential requires leveraging innate immunity, necessitating the integration of biomaterials.

Purpose of the Study:

• To review how biomaterials can reprogram and recruit innate immune cells within tumors.
• To explore the potential of biomaterials in initiating T cell immunity against advanced cancers.
• To discuss biomaterial design strategies for enhanced innate immune cell targeting and selective immunogenicity with reduced side effects.

Main Methods:

• Literature review focusing on the intersection of biomaterials and innate immunity in cancer therapy.
• Analysis of biomaterial strategies for innate immune cell modulation and recruitment.
• Discussion of biomaterial design principles for targeted immunogenicity.

Main Results:

• Biomaterials can serve as a platform to direct innate immune responses against tumors.
• Recruitment and reprogramming of innate immune cells by biomaterials can initiate anti-cancer T cell immunity.
• Specific biomaterial designs can improve targeting and selectivity, potentially minimizing adverse effects.

Conclusions:

• Biomaterials offer a promising strategy to enhance cancer immunotherapy by harnessing innate immunity.
• The convergence of biomaterials and innate immunity is crucial for developing next-generation cancer treatments.
• Further research into biomaterial design can optimize innate immune cell-based therapies for improved clinical outcomes.